Program
deucravacitinib
Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.
Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.
Drug pageDeucravacitinib: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 5912 open or running | phase 4since Jul 27, 2022 | Oct 3, 2016 | Nov 18, 2026phase 3 · NCT05946941 |
| AbbVieits history only | 10 open or running | phase 4since Mar 21, 2024 | Mar 21, 2024 | none ahead |
Also a collaborator on its studies: Covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 44 earlier studies, Oct 3, 2016 to Jun 30, 2021.
- Jun 9, 2020Named deucravacitinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986165
- Jul 27, 2022Phase 4 study in PsoriasisNCT05478499 · 154 enrolled · United States, France, Germany and more
- Sep 23, 2022Phase 2 study in Alopecia AreataNCT05556265 · 94 enrolled · United States, Australia, Canada and more
- Nov 8, 20222 phase 3 studies in Lupus Erythematosus, SystemicNCT05617677, NCT05620407
- Jan 16, 2023Phase 4 study in PsoriasisNCT05701995 · 180 enrolled · United States, Puerto Rico
- Jul 7, 2023Phase 3 study in Sjogren's SyndromeNCT05946941 · 774 enrolled · United States, Argentina, Australia and more
- Sep 12, 2023Phase 4 study in Palmoplantar PsoriasisNCT06042920 · 130 enrolled · United States, Argentina, Canada
- Jun 21, 2024Phase 4 study in Healthy VolunteersNCT06476834 · 8 enrolled · United States
- Aug 21, 2024Phase 1 study in Healthy ParticipantsNCT06566768 · 52 enrolled · United Kingdom
- Jan 22, 2025Phase 1 study in Healthy ParticipantsNCT06851871 · 26 enrolled · United States
- Mar 6, 2025Phase 3 study in Arthritis, JuvenileNCT06869551 · 60 planned · United States, Brazil, Bulgaria and more
- Mar 12, 2025Phase 4 study in Lupus Erythematosus, SystemicNCT06875960 · 35 planned · United States
- May 13, 2025Phase 3 study in PsoriasisNCT06979453 · 366 planned · United States, Argentina, Belgium and more
- Aug 4, 2025Phase 3 study in Plaque PsoriasisNCT07116967 · 3,040 planned · United States, Argentina, Australia and more
- Aug 25, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07791199 · 2,300 planned
Ahead
- Nov 18, 2026Primary completion: phase 3 study in Sjogren's SyndromeNCT05946941
- Jan 31, 2028Primary completion: phase 4 study in Lupus Erythematosus, SystemicNCT06875960
- Jan 1, 2029Primary completion: phase 3 study in PsoriasisNCT04772079
- Oct 12, 2029Primary completion: phase 3 study in PsoriasisNCT06979453
TargetBeta
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
All 59 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07791199Lupus Erythematosus, Systemic | 3 | Not yet recruiting | Oct 31, 2030 | 2,300 |
| NCT07116967Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Recruiting | Jan 16, 2031 | 3,040 |
| NCT06979453Psoriasis · United States, Argentina, Belgium and more | 3 | Recruiting | Oct 12, 2029 | 366 |
| NCT06875960Lupus Erythematosus, Systemic · United States | 4 | Recruiting | Jan 31, 2028 | 35 |
| NCT06869551Arthritis, Juvenile · United States, Brazil, Bulgaria and more | 3 | Recruiting | Mar 6, 2030 | 60 |
| NCT06851871Healthy Participants · United States | 1 | Completed | Apr 4, 2025 | 26 |
| NCT06566768Healthy Participants · United Kingdom | 1 | Completed | Jun 13, 2025 | 52 |
| NCT06476834Healthy Volunteers · United States | 4 | Completed | Nov 2, 2024 | 8 |
| NCT06042920Palmoplantar Psoriasis · United States, Argentina, Canada | 4 | Terminated | Apr 25, 2025 | 130 |
| NCT05946941Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 18, 2026 | 774 |
| NCT05701995Psoriasis · United States, Puerto Rico | 4 | Completed | Aug 23, 2024 | 180 |
| NCT05620407Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 19, 2026 | 513 |
| NCT05617677Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Oct 19, 2026 | 516 |
| NCT05556265Alopecia Areata · United States, Australia, Canada and more | 2 | Terminated | Jan 6, 2024 | 94 |
| NCT05478499Psoriasis · United States, France, Germany and more | 4 | Completed | Jan 11, 2024 | 154 |
| NCT04949269Healthy Participants · United States | 1 | Completed | Jan 3, 2022 | 61 |
| NCT04908202Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 10, 2024 | 670 |
| NCT04908189Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 7, 2024 | 729 |
| NCT04877990Crohn Disease · United States, Australia, Canada and more | 2 | Completed | Aug 29, 2023 | 67 |
| NCT04857034Lupus Erythematosus, Discoid · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 22, 2024 | 74 |
| NCT04772079Psoriasis · Argentina, Australia, Brazil and more | 3 | Recruiting | Jan 1, 2029 | 153 |
| NCT04671953Healthy Participants · United States | 1 | Completed | Mar 3, 2021 | 36 |
| NCT04613518Colitis, Ulcerative · United States, Australia, Canada and more | 2 | Completed | May 31, 2023 | 38 |
| NCT04536961Healthy Volunteers · United Kingdom | 1 | Completed | Dec 25, 2020 | 56 |
| NCT04305899Healthy Participants · United States | 1 | Completed | Nov 25, 2020 | 40 |
| NCT04249284Healthy Participants · United States | 1 | Completed | Mar 15, 2020 | 18 |
| NCT04209699Healthy Participants · United States | 1 | Completed | Feb 4, 2020 | 18 |
| NCT04167462Psoriasis · China, Korea, Republic of, Taiwan | 3 | Completed | Mar 8, 2021 | 220 |
| NCT04113668Healthy Participants · United States | 1 | Completed | Nov 19, 2019 | 48 |
| NCT04086719Healthy Male Volunteers · United States | 1 | Completed | Oct 29, 2019 | 16 |
| NCT04065932Lupus · United Kingdom | 1 | Completed | Dec 8, 2019 | 33 |
| NCT04055506Healthy Participants · United States | 1 | Completed | Sep 21, 2019 | 16 |
| NCT04036435Psoriasis · United States, Australia, Canada and more | 3 | Completed | Jul 21, 2026 | 1,466 |
| NCT03979248Healthy · Netherlands | 1 | Completed | Jul 7, 2019 | 21 |
| NCT03956953Autoimmune Diseases · China | 1 | Completed | Sep 25, 2019 | 135 |
| NCT03934216Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Jun 13, 2021 | 131 |
| NCT03943147Lupus Nephritis · United States, Australia, Belgium and more | 2 | Terminated | Oct 29, 2020 | 16 |
| NCT03930602Healthy · United States | 1 | Completed | May 27, 2019 | 16 |
| NCT03924427Psoriasis · Japan | 3 | Completed | Mar 24, 2021 | 74 |
| NCT03920267Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Completed | Mar 21, 2025 | 261 |
| NCT03890809Liver Diseases · Czechia, Hungary, Slovakia | 1 | Completed | Nov 30, 2019 | 32 |
| NCT03890770Renal Insufficiency · United States, Czechia, Hungary and more | 1 | Completed | Feb 7, 2020 | 44 |
| NCT03881059Active Psoriatic Arthritis · United States, Czechia, Germany and more | 2 | Completed | Apr 27, 2020 | 203 |
| NCT03873415Psoriasis · United States | 1 | Completed | May 1, 2019 | 9 |
| NCT03739788Healthy Participants · United Kingdom | 1 | Completed | Feb 11, 2019 | 8 |
| NCT03751228Healthy Participants · United States | 1 | Completed | Nov 26, 2018 | 9 |
| NCT03660436Healthy Participants · United States | 1 | Completed | Oct 10, 2018 | 131 |
| NCT03624127Psoriasis · United States, Canada, China and more | 3 | Completed | Sep 2, 2020 | 666 |
| NCT03611751Psoriasis · United States, Australia, Canada and more | 3 | Completed | Nov 29, 2020 | 1,020 |
| NCT03599622Crohn Disease · United States, Australia, Belgium and more | 2 | Terminated | Dec 12, 2022 | 239 |
| NCT03541564Lupus Erythematosus, Systemic · United States | 1 | Completed | Sep 4, 2018 | 84 |
| NCT03419910Psoriasis · United States | 1 | Completed | May 4, 2018 | 54 |
| NCT03402087Arthritis, Psoriatic · Netherlands | 1 | Completed | Mar 20, 2018 | 30 |
| NCT03262727Lupus Erythematosus, Systemic · United States | 1 | Completed | Nov 23, 2017 | 49 |
| NCT03254784Lupus Erythematosus, Systemic · United States | 1 | Completed | Nov 4, 2017 | 49 |
| NCT03252587Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Jun 29, 2021 | 363 |
| NCT03044873Autoimmune Diseases · United States | 1 | Completed | Mar 14, 2017 | 20 |
| NCT03004768Psoriasis · United States | 1 | Completed | Feb 27, 2017 | 6 |
| NCT02931838Psoriasis · United States, Australia, Canada and more | 2 | Completed | Nov 16, 2017 | 268 |
How it is read
Names in the registry
- “BMS-986165”, 34 entries
- “Deucravacitinib”, 21 entries
- “BMS-986165 Tablet”, 2 entries
- “BMS-986165 Dose A”, 1 entry
- “BMS-986165 Dose B”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 16 studies
- Lupus Erythematosus, Systemic, 9 studies
- Arthritis, Psoriatic, 4 studies
- Crohn Disease, 2 studies
- Colitis, Ulcerative, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.